搡老女人多毛老妇女中国,日韩亚洲欧美中文高清在线,人妻少妇一区二区三区,色妞色综合久久夜夜,日本熟妇xxxx

Your Good Partner in Biology Research

  1. Home
  2. 抗體
  3. 重組抗體
  4. CDK6 Recombinant Monoclonal Antibody

CDK6 Recombinant Monoclonal Antibody

  • 中文名稱：
    CDK6重組抗體
  • 貨號：
    CSB-RA555745A0HU
  • 規(guī)格：
    ￥1320
  • 圖片：
    • Western Blot
      Positive WB detected in: JK whole cell lysate(20μg), K562 whole cell lysate(20μg), SY5Y whole cell lysate(20μg), HepG2 whole cell lysate(20μg), COLO205 whole cell lysate(20μg)
      All lanes: CDK6 antibody at 1:1000
      Secondary
      Goat polyclonal to rabbit IgG at 1/40000 dilution
      Predicted band size: 37 kDa
      Observed band size: 37 kDa
      Exposure time: 120s
    • Immunofluorescence staining of U251 cell with CSB-RA555745A0HU at 1:10, counter-stained with DAPI. The cells were fixed in 4% formaldehyde and and permeated by 0.2% TritonX-100 for 15 min. Then 10% normal goat serum to block non-specific protein-protein interactions . The cells were then incubated with the antibody overnight at 4℃. The secondary antibody was Alexa Fluor 488-congugated AffiniPure Goat Anti-Rabbit IgG(H+L).
    • Immunofluorescence staining of U251 cell with 5% goat serum, counter-stained with DAPI. The cells were fixed in 4% formaldehyde and blocked in 10% normal Goat Serum. The cells were then incubated with the antibody overnight at 4C. The secondary antibody was Alexa Fluor 488-congugated AffiniPure Goat Anti-Rabbit IgG(H+L).
    • Immunofluorescence staining of Hela cell with CSB-RA555745A0HU at 1:10, counter-stained with DAPI. The cells were fixed in 4% formaldehyde and and permeated by 0.2% TritonX-100 for 15 min. Then 10% normal goat serum to block non-specific protein-protein interactions . The cells were then incubated with the antibody overnight at 4℃. The secondary antibody was Alexa Fluor 488-congugated AffiniPure Goat Anti-Rabbit IgG(H+L).
    • Immunofluorescence staining of Hela cell with 5% goat serum, counter-stained with DAPI. The cells were fixed in 4% formaldehyde and blocked in 10% normal Goat Serum. The cells were then incubated with the antibody overnight at 4C. The secondary antibody was Alexa Fluor 488-congugated AffiniPure Goat Anti-Rabbit IgG(H+L).
    • IHC image of CSB-RA555745A0HU diluted at 1:50 and staining in paraffin-embedded human tonsil tissue performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4°C overnight. The primary is detected by a Goat anti-rabbit polymer IgG labeled by HRP and visualized using 0.05% DAB. Secondary antibody only control: uses 1% BSA instead of primary antibody
    • IHC image of CSB-RA555745A0HU diluted at 1:50 and staining in paraffin-embedded human colorectal cancer performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4°C overnight. The primary is detected by a Goat anti-rabbit polymer IgG labeled by HRP and visualized using 0.05% DAB. Secondary antibody only control: uses 1% BSA instead of primary antibody
    • Immunoprecipitating CDK6 in K562whole cell lysate
      Lane 1: CSB-RA555745A0HU(3μg)+ K562 whole cell lysate(220μg)
      Lane 2: K562 whole cell lysate(30μg)
      Lane 3:Rabbit control IgG instead of CSB-RA010605A0HU?in?K562?whole?cell?lysate
      For western blotting, a HRP-conjugated Protein G antibody was used as the secondary antibody (1/40000)
  • 其他：

產(chǎn)品詳情

  • 產(chǎn)品描述：
    CDK6 Recombinant Monoclonal Antibody（CSB-RA555745A0HU）是針對細(xì)胞周期依賴性激酶6（CDK6）開發(fā)的高特異性抗體產(chǎn)品。CDK6作為細(xì)胞周期調(diào)控的核心蛋白，通過與D型周期蛋白結(jié)合驅(qū)動G1/S期轉(zhuǎn)換，其異常表達(dá)與多種腫瘤發(fā)生發(fā)展密切相關(guān)。本抗體經(jīng)ELISA、Western Blot（WB）和免疫沉淀（IP）等多平臺驗(yàn)證，在WB實(shí)驗(yàn)中可識別內(nèi)源性CDK6蛋白并呈現(xiàn)清晰的特異性條帶，推薦使用稀釋比例為1:500至1:5000；IP實(shí)驗(yàn)中也表現(xiàn)出高效的特異性結(jié)合能力，建議稀釋范圍為1:200至1:1000。該抗體適用于細(xì)胞裂解液、組織提取物等多種樣本類型，可滿足研究人員在腫瘤信號通路解析、細(xì)胞周期調(diào)控機(jī)制探索以及抗腫瘤藥物靶點(diǎn)驗(yàn)證等領(lǐng)域的實(shí)驗(yàn)需求。其重組單克隆抗體的特性確保了批次間的高度一致性，為蛋白質(zhì)相互作用研究、功能驗(yàn)證實(shí)驗(yàn)及分子機(jī)制研究提供了可靠工具，特別適用于需要高重復(fù)性的定量分析與功能學(xué)研究場景。
  • Uniprot No.：
  • 基因名：
  • 別名：
    Cyclin-dependent kinase 6 (EC 2.7.11.22) (Cell division protein kinase 6) (Serine/threonine-protein kinase PLSTIRE), CDK6, CDKN6
  • 反應(yīng)種屬：
    Human
  • 免疫原：
    A synthesized peptide derived from human CDK6
  • 免疫原種屬：
    Homo sapiens (Human)
  • 標(biāo)記方式：
    Non-conjugated
  • 克隆類型：
    Monoclonal
  • 抗體亞型：
    Rabbit IgG
  • 純化方式：
    Affinity-chromatography
  • 克隆號：
    8G3
  • 濃度：
    It differs from different batches. Please contact us to confirm it.
  • 保存緩沖液：
    Rabbit IgG in phosphate buffered saline, pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.
  • 產(chǎn)品提供形式：
    Liquid
  • 應(yīng)用范圍：
    ELISA, WB, IHC, IF, IP
  • 推薦稀釋比：
    Application Recommended Dilution
    WB 1:500-1:5000
    IHC 1:50-1:100
    IF 1:10-1:100
    IP 1:1000-1:2000
  • Protocols：
  • 儲存條件：
    Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
  • 貨期：
    Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
  • 用途：
    For Research Use Only. Not for use in diagnostic or therapeutic procedures.

產(chǎn)品評價

靶點(diǎn)詳情

  • 功能：
    Serine/threonine-protein kinase involved in the control of the cell cycle and differentiation; promotes G1/S transition. Phosphorylates pRB/RB1 and NPM1. Interacts with D-type G1 cyclins during interphase at G1 to form a pRB/RB1 kinase and controls the entrance into the cell cycle. Involved in initiation and maintenance of cell cycle exit during cell differentiation; prevents cell proliferation and regulates negatively cell differentiation, but is required for the proliferation of specific cell types (e.g. erythroid and hematopoietic cells). Essential for cell proliferation within the dentate gyrus of the hippocampus and the subventricular zone of the lateral ventricles. Required during thymocyte development. Promotes the production of newborn neurons, probably by modulating G1 length. Promotes, at least in astrocytes, changes in patterns of gene expression, changes in the actin cytoskeleton including loss of stress fibers, and enhanced motility during cell differentiation. Prevents myeloid differentiation by interfering with RUNX1 and reducing its transcription transactivation activity, but promotes proliferation of normal myeloid progenitors. Delays senescence. Promotes the proliferation of beta-cells in pancreatic islets of Langerhans. May play a role in the centrosome organization during the cell cycle phases.
  • 基因功能參考文獻(xiàn)：
    1. CDK6 inhibition and MiR-320c overexpression attenuated IL-1beta-induced increases in expression of inflammatory products such as iNOS and MMP13 and decreased the expression of anabolic products such as COL2A1 and aggrecan. PMID: 30466085
    2. Our data suggested that miR-29a could play an important role in inhibiting proliferation and motility of cancerous Schwann cells, and may suppress tumor growth through upregulation of CDK6. PMID: 29023945
    3. High CDK6 Expression is associated with Oral Squamous Cell Carcinomas. PMID: 29693970
    4. The results indicate that C-glycosyl flavone may exert induction of apoptosis, cell cycle arrest and inhibition of angiogenesis via CDK6. Thus, targeting CDK6 using C-glycosyl flavone may serve as a novel therapeutic approach for the treatment of breast, hepatic and colon cancers. PMID: 29806604
    5. the miR494/CDK6 axis has a significant tumorsuppressive effect on osteosarcoma. PMID: 28990071
    6. High CDK6 expression is associated with bladder carcinoma. PMID: 27484176
    7. Molecular dynamics simulations showed that the free energy barrier of the transition from open to closed state decreased ~47.2% after Thr177 phosphorylation, increasing the flexibility around the ATP-binding pocket. Binding preferences of 10 different inhibitors to open or closed state were also investigated. PMID: 29108955
    8. miRNA-195 was associated with tumor malignancy grade and might be involved in the development and progression of OVC. In addition, CDK6 was predicted to be a target gene of miRNA-195 and obviously increased in both OVC and OSCC. PMID: 28621315
    9. Results show that miR-218-5p is increased in bone metastases and promotes breast cancer cell proliferation by activating wnt signaling. PMID: 27738322
    10. Upregulation of CDK6 may be an important mechanism in overcoming fulvestrant-mediated growth inhibition in breast cancer cells. PMID: 27252418
    11. the MYU/hnRNP-K/CDK6 pathway functions downstream of Wnt/c-Myc signaling and plays a critical role in the proliferation and tumorigenicity of colon cancer cells. PMID: 27568568
    12. The deletion of CBX3 directly enforces the expression of CDK6 and p21. PMID: 28193906
    13. CDK6-mediated suppression of CD25 is required for initiation of T-ALL by activated Notch1 PMID: 26707936
    14. CDK6 overexpression is associated with cancer. PMID: 27206849
    15. High CDK6 expression is associated with Melanoma. PMID: 26988987
    16. Palbociclib can overcome mutations in cyclin dependent kinase 6 that break hydrogen bonds between the drug and the protein PMID: 28168755
    17. Our study proved that the CDK6 gene is a target of miR-637, and demonstrated the regulatory association between miR-637 and CDK6 PMID: 27794186
    18. miR-1299 inhibited CDK6 expression and bound to the 3'UTR of CDK6. PMID: 27490780
    19. Results show that NEAT1 regulated CDK6 expression in laryngeal squamous cell cancer (LSCC) cells which was mediated by miR-107; NEAT1 plays an oncogenic role in the tumorigenesis of LSCC. PMID: 26822763
    20. lower expression in cisplatin-resistant non-small-cell lung carcinoma PMID: 25703099
    21. three uniquely identified proteins (CDK6 , galectin-3-binding protein and LDH C) were found, which show tight connection with prostate cancer and presence of all of them was previously linked to certain aspects of prostate cancer PMID: 26503549
    22. These data enhance our understanding of the important role that GAS5 plays in the molecular etiology of GC and suggest a potential of GAS5 as a new therapeutic target for GC treatment. PMID: 26278580
    23. MiR-26a and mir-584 inhibit the binding of hnRNP A1-CDK6 mRNA and induce colorectal cancer cell apoptosis. PMID: 26494299
    24. only miR-34a was prognostic for RFS (RR, 11.5; P = 0.027). miR-34a expression was inversely correlated with that of c-MET and CDK6 in non-small cell lung cancer , and had prognostic significance for RFS, especially in adenocarcinoma patients. PMID: 26104764
    25. We conclude that Bz-surviving MM cells display a GRP78(HIGH)/p21(HIGH)/CDK6(LOW)/P-Rb(LOW) profile, and these markers may identify quiescent MM cells capable of fueling recurrences. PMID: 26025442
    26. differential expression of CDK6 underlies heterogeneity in stem cell quiescence states that functionally regulates this highly regenerative system PMID: 25704240
    27. LINE-1 hypomethylation was associated with a higher cancer recurrence and CDK6 messenger RNA expression levels were inversely associated with LINE-1 methylation in hepatocellular carcinomas. PMID: 25319577
    28. miR-320c could inhibit the proliferation, migration and invasion of bladder cancer cells via regulating CDK6. PMID: 25178497
    29. SUMO1 modification stabilizes CDK6 protein and drives the cell cycle and glioblastoma progression. PMID: 24953629
    30. Cooperation of DLC1 and CDK6 affects breast cancer clinical outcome PMID: 25425654
    31. Our data suggest that miR-377 can suppress proliferation in MG-63 cells in part by targeting CDK6. PMID: 25577249
    32. genetic variants in CDK6 and PADI4 were associated with anti-citrullinated cyclic peptide status in rheumatoid arthritis DRB1*04 negative patients PMID: 25138370
    33. CDK6 is a direct target of MLL fusion proteins, playing an important role in the proliferation advantage of MLL-rearranged ALL cells. PMID: 24736461
    34. The addition of CDK4/6 inhibitor palbociclib to letrozole in this phase 2 study significantly improved progression-free survival in women with advanced oestrogen receptor-positive and HER2-negative breast cancer. PMID: 25524798
    35. results suggest that DCK6 is a putative target of miR504 in of hypopharyngeal squamous cell carcinoma. PMID: 24647829
    36. cases with CDK6-positive expression experienced worse clinical outcome compared with those with CDK6-negative expression, supporting the oncogenic role of CDK6 in ESCC. PMID: 24423610
    37. these findings identify a direct relationship between control of the cell cycle by CDK6 and SAMHD1 activity, which is important for replication of lentiviruses, as well as other viruses whose replication may be regulated by intracellular dNTP availability. PMID: 25015816
    38. Findings begin to elucidate the role of miR-145 as an important regulator of chemoresistance in ovarian cancer by controlling both Cdk6 and Sp1. PMID: 24510775
    39. overexpression of hsa-miR-4516 downregulates STAT3, p-STAT3, CDK6, and UBE2N proteins that are consistently upregulated in psoriasis and induces apoptosis in HaCaT cells. PMID: 24610393
    40. An evolving tumor can only derive full benefit from from overexpression of CDK6 in the absence of P16INK4A. PMID: 24161991
    41. MYC-dependent breast cancer cells possess high MYC expression and high level of MYC phosphorylation, but are not sensitive to inhibition of CDK6. PMID: 24444383
    42. This interaction suggests that CDK6 regulates EYA2 activity, a mechanism that could be important in development and in cancer. PMID: 24196439
    43. Gas5 negatively regulates CDK6 (cyclin-dependent kinase 6) expression in vitro and in vivo in pancreatic cancer cells. PMID: 24026436
    44. data identify CDK6 as critical effector of MLL fusions in leukemogenesis that might be targeted to overcome the differentiation block associated with MLL-rearranged acute myeloid leukemia PMID: 24764564
    45. Data indicate CDK6 as a putative target of miR-105 which is likely a main contributor to the inhibition of tumour cell growth observed in our assays. PMID: 23950948
    46. CDK6 rs42041 was associated with a remitting course of juvenile idiopathic arthritis. PMID: 24347572
    47. We propose that the identified CDK6 mutation leads to reduced cell proliferation and impairs the correct functioning of the centrosome in microtubule organization and its positioning near the nucleus which are key determinants during neurogenesis. PMID: 23918663
    48. Downregulation of GAS5 promotes bladder cancer cell proliferation, partly by regulating CDK6. PMID: 24069260
    49. results showed that let-7a acted as a tumor suppressor in ES by targeting CDK6, and it may provide novel diagnostic and therapeutic options for human Ewing sarcoma clinical operation in future PMID: 24383407
    50. CDK6 was identified as a novel functional target of miR200a. Our data indicate that miR200a functions as a potential tumor suppressor in HCC. PMID: 24009066

    顯示更多

    收起更多

  • 相關(guān)疾?。?/div>
    Microcephaly 12, primary, autosomal recessive (MCPH12)
  • 亞細(xì)胞定位：
    Cytoplasm. Nucleus. Cell projection, ruffle. Cytoplasm, cytoskeleton, microtubule organizing center, centrosome.
  • 蛋白家族：
    Protein kinase superfamily, CMGC Ser/Thr protein kinase family, CDC2/CDKX subfamily
  • 組織特異性：
    Expressed ubiquitously. Accumulates in squamous cell carcinomas, proliferating hematopoietic progenitor cells, beta-cells of pancreatic islets of Langerhans, and neuroblastomas. Reduced levels in differentiating cells.
  • 數(shù)據(jù)庫鏈接：

    HGNC: 1777

    OMIM: 603368

    KEGG: hsa:1021

    STRING: 9606.ENSP00000265734

    UniGene: Hs.119882